Reneo Pharmaceuticals, Inc. (RPHM) Stock Overview
Explore Reneo Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Reneo Pharmaceuticals, Inc. (RPHM)
Key Financials
Key Financials
Market Cap
60.8M
P/E Ratio
-5.21
EPS (TTM)
$-16.80
ROE
-0.13%
RPHM Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Reneo Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of RPHM on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.
Key metrics behind Reneo Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -5.21 and a market capitalization of 60.8M. Combined with our AI analysis, these give both institutional and retail investors a clear view of RPHM on the NASDAQ.